Jyong Biotech Ltd. (MENS) Stock Price & Analysis
Jyong Biotech Ltd. (MENS) closed at USD 1.98 on Thursday, October 15, 2026, down 3.41% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.05; the Oct 15, 2026 session ranged USD 1.95–2.07 on volume of 142,577 shares. Market capitalization is $150.53M, with a 52-week range of USD 1.43–63 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MENS.md
Key facts (MENS)
- Analysts: None.
- Total return with dividends: 1Y -96.6% vs S&P 500 +18.1%; 5Y -75.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD —, revenue estimate $0K.
Analysts (MENS)
Consensus None.
Total return (dividends reinvested) (MENS)
| 1Y (from 2025-10-16) | 5Y (from 2025-06-16) | |
|---|---|---|
| Total return | -96.6% | -75.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -96.7% | -65.0% |
| Volatility (annualized) | 209.9% | 216.0% |
| Max drawdown | -97.6% (Oct 2025→Feb 2026) | -97.6% (Sep 2025→Feb 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 1.98 |
|---|---|
| Change | ▼ 3.41% (down) |
| Previous Close | USD 2.05 |
| Open | USD 2.03 |
| Day Range | USD 1.95 – 2.07 |
| 52-Week Range | USD 1.43 – 63 |
| Volume | 142,577 shares |
| Market Cap | $150.53M |
| Exchange | NGM |
Technical Analysis (MENS)
Nexqual's technical model rates MENS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.35 (neutral) |
| vs SMA50 | Below (USD 2.12) |
| MACD | -0.03 (negative) |
Analyst Ratings (MENS)
Wall Street analysts rate MENS "None", per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | None |
|---|
Earnings (MENS)
| Next Earnings Date | 2026-11-12 |
|---|
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (MENS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.45 |
| Total Cash | $1.18M |
| Total Debt | $18.55M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (MENS)
Nexqual rates Jyong Biotech Ltd.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $1M cash vs $19M debt |
| Cash Flow | Weak — Operating cash flow -$3M (TTM) |
| Efficiency | Mixed — No data |
Ownership (MENS)
| Insider Ownership | +62.20% |
|---|---|
| Institutional Ownership | +0.77% |
| Shares Outstanding | 74.23M |
| Float | 26.94M |
| Short % of Float | +0.54% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (MENS)
Jyong Biotech Ltd. is led by Fu-Feng Kuo (age 67), CEO & Chairwoman of the Board, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Chairwoman of the Board | Fu-Feng Kuo (age 67) |
|---|---|
| Chief Financial Officer | Wei Zhang (age 44) |
| CTO & Director | Fenglin Hsu (age 76) |
Major Backers & Investors (MENS)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.63% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt